Atopic dermatitis or atopic eczema is a chronic, relapsing, familial, symmetric and pruritic inflammatory skin disease that commonly presents during early infancy and childhood, but can persist or start in adulthood.
It is commonly associated with elevated serum immunoglobulin E levels and a personal or family history of allergies, allergic rhinitis and asthma.
It is one of the most common skin diseases afflicting both children and adults.
Patients with moderate-to-severe atopic dermatitis (AD) were more likely to have clinically meaningful responses when treated with dupilumab at doses of 300 mg either weekly or every 2 weeks compared with those on placebo, according to a post hoc analysis of the phase III SOLO 1 and SOLO 2* trials presented as a poster at AAD 2019.
Current evidence shows dupilumab and cyclosporine as effective treatment for severe atopic dermatitis (AD), reports a recent systematic review, adding that long-term safety and efficacy of biologic medications require further research.
Two novel investigational topical agents show potential in improving symptoms of atopic dermatitis, according to early phase trials presented at the Inflammatory Skin Disease Summit (ISDS) in Vienna, Austria.
Acidity of the skin appears to be significantly higher in atopic dermatitis (AD) patients than in controls without the condition, indicating that increased skin pH may heighten the risk of developing AD, according to a study.
Most clinical guidelines recommend daily bathing in lukewarm water, followed by the application of moisturizers, in the treatment of atopic dermatitis (AD), according to an expert who presented at the 23rd Asian-Australasian Regional Conference of Dermatology (RCD 2018) held in Surabaya, Indonesia.
Although many patients with atopic dermatitis (AD) use antihistamines, no high-level evidence exists to prove that nonsedating antihistamines reduce itch in patients with AD or provide benefit in controlling AD symptoms, except perhaps sleep and AD comorbidities such as allergic rhinitis, according to a study.
Lebrikizumab, an interleukin (IL)-13 monoclonal antibody, taken every 4 weeks and in combination with topical corticosteroid (TCS) is safe and effective in patients with moderate-to-severe atopic dermatitis (AD), results from a phase II study have shown.